628 POSTER Single agent and combination treatment studies with the telomerase inhibitor GRN163L in ovarian cancer and non-small cell lung carcinoma (NSCLC) xenograft models

N.Go; Y.Li; R.Tressler

首页> 外文期刊>European Journal of Cancer Supplements >628 POSTER Single agent and combination treatment studies with the telomerase inhibitor GRN163L in ovarian cancer and non-small cell lung carcinoma (NSCLC) xenograft models

【24h】

628 POSTER Single agent and combination treatment studies with the telomerase inhibitor GRN163L in ovarian cancer and non-small cell lung carcinoma (NSCLC) xenograft models

机译：628 POSTER端粒酶抑制剂GRN163L在卵巢癌和非小细胞肺癌（NSCLC）异种移植模型中的单药和联合治疗研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共1页
作者
N.Go; Y.Li; R.Tressler;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 353 POSTER Therapeutic potential of YM155 alone and in combination with chemotherapeutics against human non-small cell lung cancer in carcinoma xenograft models [J] . K.Yamanaka, T.Nakahara, A.Kita, European Journal of Cancer Supplements . 2008,第12期

机译：353 POSTER在癌症异种移植模型中，单独使用YM155以及与化学疗法联合使用对人非小细胞肺癌的治疗潜力
2. 353 POSTER Therapeutic potential of YM155 alone and in combination with chemotherapeutics against human non-small cell lung cancer in carcinoma xenograft models [J] . K.Yamanaka, T.Nakahara, A.Kita, European Journal of Cancer Supplements . 2008,第12期

机译：353 POSTER在癌症异种移植模型中，单独使用YM155以及与化学疗法联合使用对人非小细胞肺癌的治疗潜力
3. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. [J] . Ling YH, Aracil M, Jimeno J European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2009,第10期

机译：PM02734（依立信菌素）作为单一药物并与厄洛替尼联用的分子药效学;在人类非小细胞肺癌细胞系和异种移植模型中的协同活性。
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Enhancing the Therapeutic Effects of Low Doses of Ionizing Radiation in Non-Small Cell Lung Cancers Using a Combination of PARP Inhibitors and DNA Demethylating Agents. [D] . Biondi, Christopher Anthony. 2016

机译：使用PARP抑制剂和DNA去甲基化剂的组合增强非小细胞肺癌低剂量电离辐射的治疗效果。
6. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models [O] . Yi-He Ling, Miguel Aracil, José Jimeno, -1

机译：PM02734（ELISIDESIN）作为单一剂的分子药效学和与厄洛替尼结合;人类非小细胞肺癌细胞系和异种移植模型的协同活性
7. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models [O] . Yi-He Ling, Miguel Aracil, José Jimeno, 2009

机译：PM02734（ELISIDESIN）作为单一剂的分子药效学和与厄洛替尼结合;人类非小细胞肺癌细胞系和异种移植模型的协同活性

628 POSTER Single agent and combination treatment studies with the telomerase inhibitor GRN163L in ovarian cancer and non-small cell lung carcinoma (NSCLC) xenograft models

著录项

相似文献

相关主题

期刊订阅